C. Meador

发表

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Christine M. Micheel, William Pao, Zhongming Zhao, 2014, Clinical Cancer Research.

Longitudinal Cell‐Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse

C. Raymond, Y. Shyr, C. Lovly, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Longitudinal monitoring of circulating tumor DNA and peripheral T cell repertoire in patients with small cell lung cancer.

Dan DiPasquo, C. Raymond, T. Shaffer, 2017 .

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.

W. Pao, C. Meador, 2015, Cancer discovery.

Targeting EGFR Exon 20 Insertions in NSCLC: Recent Advances and Clinical Updates

L. Sequist, C. Meador, Z. Piotrowska, 2021 .

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Amanda R. Kulick, M. Ladanyi, W. Pao, 2017, Cancer research.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

Junfeng Xia, Peilin Jia, William Pao, 2013, Genome research.

resistance lines identifies spectrum of DNA changes associated with drug inhibitor-sensitive and-resistant EGFR mutant lung cancer cell Next-generation sequencing of paired tyrosine kinase Material Supplemental

Zhongming Zhao, P. Jia, W. Pao, 2013 .

Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

X. Chen, M. Ladanyi, E. Stanchina, 2014 .

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

W. Pao, N. Gray, D. Colvin, 2016, Cancer research.

EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

W. Pao, N. Gray, D. Colvin, 2016 .

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

A. Hata, C. Meador, 2020, Pharmacology & therapeutics.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

Effective Cancer Genotyping—Many Means to One End

G. Oxnard, C. Meador, 2019, Clinical Cancer Research.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

F. Hyder, W. Pao, K. Politi, 2015, Clinical Cancer Research.

High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content

C. Paweletz, M. Rabin, G. Oxnard, 2021, JCO precision oncology.

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

X. Chen, Zhongming Zhao, M. Ladanyi, 2014, Molecular Cancer Therapeutics.

Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center.

Brian W. Powers, Justin P. Tuwatananurak, Lisa S. Rotenstein, 2019, Circulation. Heart failure.

Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.

J. Warner, J. Bordeaux, C. Lovly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors

C. Lovly, C. Meador, 2015, Nature Medicine.

Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

Linda T. Nieman, N. Hacohen, Keren Yizhak, 2023, bioRxiv.

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review

C. Meador, Z. Piotrowska, 2023, Translational lung cancer research.

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

L. Sequist, C. Meador, Z. Piotrowska, 2021, Cancer discovery.

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

R. Deberardinis, Jing Wang, J. Minna, 2023, Cancer cell.

Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs

L. Girard, C. Christensen, A. Farago, 2023, bioRxiv.